Construction and Biological Characterization of an Interleukin-12 Fusion Protein (Flexi-12): Delivery to Acute Myeloid Leukemic Blasts Using Adeno-Associated Virus
Authors:
- Ian MacdonaldIMIan Macdonald
- Tim CorbettTCTim Corbett
- Graeme HackingGHGraeme Hacking
- Mark W. LowdellMLMark W. Lowdell
- H. Grant PrenticeHPH. Grant Prentice
- 10 June 1997
- journal article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 8 (9) , 1125-1135
Abstract
Interleukin-12 (IL-12) is a cytokine that exhibits pleiotropic effects on lymphocytes and natural killer cells and has been shown to have promise for the immunotherapy of cancer. The combination of the immune costimulatory molecule B7.1 and IL-12 has been shown to be synergistic for T cell activation. By transfecting tumor cells with both IL-12 and B7.1 cDNAs, it may be possible to use these modified targets as vaccines. A major obstacle in designing a vector to deliver these genes results from the structure of IL-12. Functional IL-12 is a heterodimer composed of two distinct subunits that are encoded by separate genes on different chromosomes. Production of functional IL-12 requires the coordinated expression of both genes. This presents several problems in vectors, particularly those in which additional genes, either a co-stimulatory gene or a selectable marker, are inserted. Therefore, we have constructed a single cDNA that encodes a single-chain protein, called Flexi-12, which retains all of the biological characteristics of recombinant IL-12 (rIL-12). The monomeric polypeptide Flexi-12 is able to induce the proliferation of phytohemagglutinin (PHA) blasts, induce PHA blasts to secrete interferon-gamma (IFN-gamma) and additionally, by preincubation, enhance the killing of K562 targets by PBLs. These phenomena are in a dose-dependent manner comparable to that seen with rIL-12. We have also shown that tyrosine phosphorylation of the STAT 4 transcription factor, which has been shown to be unique to the IL-12 signaling pathway, occurs with Flexi-12 at levels similar to those seen with rIL-12. We have packaged Flexi-12 into a recombinant adeno-associated virus (AAV) and used this vector to infect acute myeloid leukemic (AML) blasts. Infected AML blasts produced between 2 and 6 ng of IL-12/10(6) cells per ml per 48 hr. These studies also confirm that AAV is an efficient delivery vehicle for cytokines to leukemic cells. Direct analysis of these modified cells acting as tumor vaccines is underway.Keywords
This publication has 28 references indexed in Scilit:
- Construction of a Double Recombinant Adenovirus Vector Expressing a Heterodimeric Cytokine: In Vitro and In Vivo Production of Biologically Active Interleukin-12Human Gene Therapy, 1996
- Structure-Function Analysis of the p35 Subunit of Mouse Interleukin 12Journal of Biological Chemistry, 1995
- Construction and Characterization of Retroviral Vectors Expressing Biologically Active Human Interleukin-12Human Gene Therapy, 1994
- B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation.Journal of Experimental Medicine, 1994
- Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells.Journal of Experimental Medicine, 1994
- The interleukin‐12 subunit p40 specifically inhibits effects of the interleukin‐12 heterodimerEuropean Journal of Immunology, 1993
- IL-12: Initiation Cytokine for Cell-Mediated ImmunityScience, 1993
- Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells.Journal of Experimental Medicine, 1993
- Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells.Journal of Experimental Medicine, 1992
- Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients.Journal of Experimental Medicine, 1992